阿替普酶静脉溶栓对急性脑梗死患者凝血功能及神经损伤指标的影响

目的 探讨阿替普酶静脉溶栓对急性脑梗死患者凝血功能及神经损伤指标的影响。方法 选取2018年3月—2019年3月某医院收治的急性脑梗死患者150例作为本次研究对象,随机将其分为对照组(n=75)与治疗组(n=75)。对照组实施常规治疗方案,治疗组在对照组的基础上接受阿替普酶静脉溶栓,比较两组凝血功能和神经损伤指标情况。结果 治疗后,治疗组凝血酶原时间(PT/s)、凝血酶时间(TT/s)、活化部分凝血活酶时间(APTT/d)水平分别为(14.35±2.11)s、(20.71±2.95)s、(36.36±4.23)s,高于治疗前的(11.29±1.73)s、(6.48±2.62)s、(27.18±3.60)s,对照组治疗后PT、TT、APPT水平为(13.30±2.12)s、(19.88±1.18)s、(34.42±4.31)s,高于治疗前(11.42±1.81)s、(6.35±2.53)s、(27.81±4.25)s,治疗后,治疗组的水平高于对照组,(P值均<0.05);治疗组治疗后S100β、NSE、NIHSS分别为(27.33±4.16)ng/mL、(21.56±4.32)ng/mL、(7.42±1.12)分,低于治疗前的(30.45±4.37)ng/mL、(30.99±4.27)ng/mL、(14.57±2.21)分,对照组治疗后S100β、NSE、NIHSS为(29.01±4.46)ng/mL、(23.12±4.23)ng/mL、(10.11±1.58)分,低于治疗前的(30.23±4.35)ng/mL、(32.31±4.45)ng/mL、(14.48±2.36)分,差异具有统计学意义(P值均<0.05)。结论 对急性脑梗死患者实施阿替普酶静脉溶栓治疗,能够改善急性脑梗死患者神经功能、延长凝血时间,治疗效果显著。

Effect of intravenous thrombolysis with alteplase on coagulation function and nerve injury indexes in patients with acute cerebral infarction

Objective To investigate the effect of intravenous thrombolysis with alteplase on coagulation function and nerve injury indexes in the patients with acute cerebral infarction. Methods A total of 150 patients with acute cerebral infarction admitted to a hospital from March 2018 to March 2019 were randomly divided into a control group (n=75) and a trial group (n=75). The control group received the routine therapy, and the trial group received the intravenous thrombolysis with alteplase on the basis of the treatment of the control group, and the coagulation function and nerve injury indexes were investigated and compared between the two groups. Results After the treatment, in the trial group, PT/s, TT/s, and APTT/d levels were (14.35±2.11) s, (20.71±2.95) s, and (36.36±4.23) s respectively, which were higher than those before the treatment . After the treatment, in the control group, PT/s, TT, and APPT levels were (13.30±2.12) s, (19.88±1.18)s, and (34.42±4.31) s respectively, which were higher than those before the treatment . After the treatment, the levels above-mentioned in the trial group were higher than those in the control group (P<0.05). After the treatment, in the trial group, S100β, NSE, and NIHSS were (27.33±4.16) ng/mL, (21.56±4.32) ng/mL, and (7.42±1.12) points respectively, which were lower than those before the treatment (30.45±4.37) ng/ml, (30.99±4.27) ng/mL, and (14.57±2.21) points. After the treatment, in the control group, S100β, NSE, NIHSS were (29.01±4.46) ng/ml, 23.12±4.23 ng/ml, and (10.11±1.58) points respectively, which were lower than those before the treatment (30.23±4.35) ng/ml, (32.31±4.45) ng/ml, and (14.48±2.36) points respectively, and in addition, the levels in the trial group were lower than those in the control group, and there were significant differences (P<0.05). Conclusion The intravenous thrombolysis with alteplase in the treatment of patients with acute cerebral infarction can improve the neurological function and prolong the coagulation time, and the therapeutic effect is significant.